PSTX Stock Overview A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Poseida Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Poseida Therapeutics Historical stock prices Current Share Price US$9.45 52 Week High US$9.58 52 Week Low US$1.87 Beta 1.64 1 Month Change 246.15% 3 Month Change 205.83% 1 Year Change 181.25% 3 Year Change 30.89% 5 Year Change n/a Change since IPO -38.44%
Recent News & Updates
Executive Chairman of the Board exercised options and sold US$200k worth of stock Dec 13
Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting Dec 10
Executive Chairman of the Board exercised options and sold US$195k worth of stock Dec 01 Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. Nov 27
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) for $930 million. Nov 26
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities Nov 26 See more updates
Executive Chairman of the Board exercised options and sold US$200k worth of stock Dec 13
Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting Dec 10
Executive Chairman of the Board exercised options and sold US$195k worth of stock Dec 01 Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. Nov 27
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) for $930 million. Nov 26
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities Nov 26
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) for $930 million. Nov 26
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Nov 15
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 08
Poseida Therapeutics, Inc. to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 Nov 06
Poseida Therapeutics, Inc. to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema Oct 26
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement Sep 30
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024 Sep 09
Poseida Therapeutics, Inc. Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with A T-Cell Engager in a Patient with Relapsed Multiple Myeloma Sep 05
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop Aug 28
Consensus revenue estimates increase by 16% Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 06 Poseida Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Aug 06
New major risk - Revenue and earnings growth Jun 07
Consensus revenue estimates increase by 59% May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry? May 21
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 15
Consensus revenue estimates increase by 13% May 02
Poseida Therapeutics, Inc., Annual General Meeting, Jun 17, 2024 Apr 28
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27% Apr 09
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma Apr 09
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024 Mar 26
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement Mar 17
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 08
Poseida Therapeutics, Inc. Announces Executive Changes Mar 08
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry? Jan 24
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too Dec 18
Price target increased by 14% to US$14.00 Dec 11
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting Dec 11
Consensus revenue estimates fall by 24% Nov 16
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10 Poseida Therapeutics, Inc. Announces Board Changes
Consensus revenue estimates increase by 11% Aug 15
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Aug 13
New major risk - Share price stability Aug 10
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 09
Price target decreased by 12% to US$11.80 Aug 09 Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC Aug 08
Price target decreased by 9.5% to US$13.40 May 11
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding Apr 17
Consensus revenue estimates decrease by 17%, EPS upgraded Mar 16
Price target decreased by 14% to US$14.00 Mar 13
Poseida Therapeutics, Inc. Announces Resignation of Eric Ostertag as Executive Chairman and Retirement from the Board of Directors, Effective February 3, 2023 Feb 01
Poseida Therapeutics, Inc. Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition Dec 12
Consensus revenue estimates increase by 268% Nov 17
Price target decreased to US$14.75 Nov 16
High number of new and inexperienced directors Nov 16
Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech Sep 04
Consensus revenue estimates increase by 630% Aug 18
Poseida Therapeutics, Inc. Announces Program Updates Aug 12
Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M Aug 11 Poseida Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $70 million. Aug 05
Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B Aug 03
Poseida Therapeutics, Inc. Announces Appointment of George M. Church as Chair of Gene Therapy Scientific Advisory Board Jul 27
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from Russell 2500 Index Jun 26
Consensus forecasts updated May 19
Poseida Therapeutics Appoints Charles M. Baum to Board of Directors May 19
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25 May 15
Price target decreased to US$23.75 Apr 27
High number of new and inexperienced directors Apr 27
Matthew Spear Informs Poseida Therapeutics, Inc. of His Intent to Resign from Chief Medical Officer Position, Effective April 22, 2022 Apr 08
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy Feb 24
Price target decreased to US$23.75 Feb 19
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 At ASCO Genitourinary Cancers Symposium Feb 18
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors Dec 21
Poseida Therapeutics, Inc. Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Poseida Therapeutics: Genome Engineering For Safer Cell Therapies Oct 30
CEO & Director exercised options to buy US$122k worth of stock. Oct 15
CEO & Director exercised options to buy US$170k worth of stock. Sep 17
CEO & Director notifies of intention to sell stock Sep 06
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit Sep 01
CEO & Director exercised options to buy US$998k worth of stock. Aug 12 Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from Russell 2500 Growth Index
CEO & Director notifies of intention to sell stock Jun 05
Poseida Therapeutics Presents Encouraging Preclinical Data Across Its Car-T and Gene Therapy Programs At the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting May 12
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry? Mar 19
Poseida Therapeutics Reports Program Updates Mar 12
CEO & Director exercised options to buy US$1.2m worth of stock. Mar 01
New 90-day high: US$11.91 Feb 26
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day Feb 25 Shareholder Returns PSTX US Biotechs US Market 7D -0.6% -3.6% -2.4% 1Y 181.3% -2.6% 23.4%
See full shareholder returns
Return vs Market: PSTX exceeded the US Market which returned 23.3% over the past year.
Price Volatility Is PSTX's price volatile compared to industry and market? PSTX volatility PSTX Average Weekly Movement 64.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: PSTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PSTX's weekly volatility has increased from 34% to 64% over the past year.
About the Company Founded Employees CEO Website 2014 350 Kristin Yarema poseida.com
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Show more Poseida Therapeutics, Inc. Fundamentals Summary How do Poseida Therapeutics's earnings and revenue compare to its market cap? PSTX fundamental statistics Market cap US$921.06m Earnings (TTM ) -US$60.76m Revenue (TTM ) US$150.86m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PSTX income statement (TTM ) Revenue US$150.86m Cost of Revenue US$172.43m Gross Profit -US$21.57m Other Expenses US$39.19m Earnings -US$60.76m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.62 Gross Margin -14.30% Net Profit Margin -40.28% Debt/Equity Ratio 67.5%
How did PSTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 01:57 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Poseida Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alec Stranahan BofA Global Research Justin Zelin BTIG Jennifer Kim Cantor Fitzgerald & Co.
Show 5 more analysts 
